Altieri Joins AACI Board of Directors
AACI is pleased to welcome Dario C. Altieri, MD, to its Board of Directors. Dr. Altieri is president and chief executive officer of the Wistar Institute, and director of The Wistar Institute Cancer Center, in Philadelphia. His term will expire in October 2019. Dr. Altieri is filling the unexpired AACI board term of Norman "Ned" Sharpless, MD. Dr. Sharpless, former director of the UNC Lineberger Comprehensive Cancer Center, was sworn in as director of the National Cancer Institute on October 17.
Dr. Altieri joined Wistar as cancer center director and its first chief scientific officer in September 2010. He succeeded Russel Kaufman, MD, as president and chief executive officer of Wistar in 2015.
The Altieri laboratory explores the mechanisms that underlie how tumor cells survive and proliferate in cancer. In particular, his laboratory is interested in how tumor cells evade the normal processes that cause cells with genetic faults to self-destruct. Understanding these mechanisms could provide new therapeutic targets and novel approaches for virtually every type of human cancer.
Born in Milan, Italy, and educated at the University of Milan School of Medicine, Dr. Altieri became a practicing clinician at the University, where he would later earn a postgraduate specialty degree in clinical and experimental hematology. In 1987, he joined the Scripps Clinic and Research Foundation in La Jolla, California, first as a research fellow and later as a member of the faculty.
In 1994, Dr. Altieri became an associate professor at the Yale University School of Medicine, was named professor in 1999, and served in that role until 2002 when he was recruited as the founding chair of the Department of Cancer Biology at the University of Massachusetts Medical School.
In 2005, he co-founded both the national Cancer Biology Training Consortium, which promotes scientific excellence in the next generation of cancer researchers; and the Pancreatic Cancer Alliance, an all-volunteer patient advocacy organization devoted to supporting pancreatic cancer research and education.